#csp2005 - Twitter Hashtag

Drew Moghanaki

@DrewMoghanaki

1 day ago

Report card for a 10 yr old dog named after a phase 3 randomized clinical trial. #CSP2005 https://t.co/YXyymBCZ5f

0

7

0

544

Drew Moghanaki

@DrewMoghanaki

6 months ago

A historical milestone occurred today at the Michael E. DeBakey VA Medical Center, where the VALOR study team, led by @LorraineC_MD, enrolled the 500th participant! Congratulations to her team and everyone involved in this randomized phase III study. #CSP2005 https://t.co/fD3WmZ7DNh

2

49

12

0

4K

Drew Moghanaki

@DrewMoghanaki

7 months ago

The primary outcome for the VALOR study (OS) has two a priori statistical analysis plans, as described below. This is because, as predicted, about 5% of the nearly 500 randomized participants refused the allocated treatment. #CSP2005

Dr Rishabh Jain

@DrRishabhOnco

7 months ago

🎯 ITT vs TPP - the most misunderstood twins in clinical trials! Both look similar in papers… but they tell completely different stories. Let’s break it down the easy way 👇 1️⃣ ITT - Intention-To-Treat 🧠 “Once randomized, always analyzed.” Even if the patient skipped doses, switched drugs, or dropped out - they stay in their original group. ➡️ Reflects real-world effectiveness ⚖️ Preserves randomization 🚫 May dilute the treatment effect 💬 Think: How the drug works in everyday clinics. 2️⃣ TPP / PP — Per-Protocol 👩‍🔬 Only those who followed every rule: correct dose, schedule, no major violations. ➡️ Reflects true biological efficacy 🚫 Excludes non-compliant patients → selection bias risk 💪 Usually shows a cleaner, stronger effect 💬 Think: How the drug works in perfect lab conditions. 🩺 In short: 📊 ITT = “Reality” analysis 🧫 PP = “Purity” analysis Together, they tell us: 👉 Does the drug work in real life AND under perfect control? 💡 Pro-tip for journal clubs: If ITT and PP give similar results → the trial is rock solid 🔥 #OncoTwitter #ClinicalTrials #MedEd #TrialDesign #Biostatistics #MedTwitter #esmo2025 @OncoAlert @ASCO @JCO_ASCO @NEJM @DanaFarber @myESMO @ESMO_Open @TheLancetOncol @TheLancet @OncBrothers

DrRishabhOnco's tweet photo. 🎯 ITT vs TPP - the most misunderstood twins in clinical trials!

Both look similar in papers…
but they tell completely different stories.
Let’s break it down the easy way 👇

1️⃣ ITT - Intention-To-Treat
🧠 “Once randomized, always analyzed.”
Even if the patient skipped doses, switched drugs, or dropped out - they stay in their original group.
➡️ Reflects real-world effectiveness
⚖️ Preserves randomization
🚫 May dilute the treatment effect
💬 Think: How the drug works in everyday clinics.

2️⃣ TPP / PP — Per-Protocol
👩‍🔬 Only those who followed every rule: correct dose, schedule, no major violations.
➡️ Reflects true biological efficacy
🚫 Excludes non-compliant patients → selection bias risk
💪 Usually shows a cleaner, stronger effect
💬 Think: How the drug works in perfect lab conditions.

🩺 In short:
📊 ITT = “Reality” analysis
🧫 PP = “Purity” analysis

Together, they tell us:
👉 Does the drug work in real life AND under perfect control?

💡 Pro-tip for journal clubs:
If ITT and PP give similar results → the trial is rock solid 🔥

#OncoTwitter #ClinicalTrials #MedEd #TrialDesign #Biostatistics #MedTwitter #esmo2025

@OncoAlert @ASCO @JCO_ASCO @NEJM @DanaFarber @myESMO @ESMO_Open @TheLancetOncol @TheLancet @OncBrothers

0

115

49

57

11K

0

18

3

6

4K

Patrick White @care_natureme

10 months ago

@DrewMoghanaki @_ShankarSiva Bravo for spotlighting the unseen efforts in VALOR. Grateful for this insight! #CSP2005

0

2

0

15

Drew Moghanaki

@DrewMoghanaki

10 months ago

It was cathartic to begin telling the untold stories of VALOR that few are aware of. Thank you @_ShankarSiva for creating a platform to shed light on the mountains being moved to complete this study. #CSP2005

Shankar Siva

@_ShankarSiva

10 months ago

📣@DrewMoghanaki - “this talk is going to make some of you uncomfortable”… 🥹 good on you Drew for pushing the boundaries in #lungcancer #radonc - Final talk of #SABR2025 🙏🏽

_ShankarSiva's tweet photo. 📣@DrewMoghanaki - “this talk is going to make some of you uncomfortable”… 🥹 good on you Drew for pushing the boundaries in #lungcancer #radonc - Final talk of #SABR2025 🙏🏽 https://t.co/GQU6J9alGh

1

38

6

1

6K

2

29

3

1

4K

Drew Moghanaki

@DrewMoghanaki

10 months ago

“I did not expect the study to take this many years to complete enrollment and randomization”. #CSP2005

0

8

0

684

Drew Moghanaki

@DrewMoghanaki

11 months ago

One of Dr. Altorki's greatest attributes is his honest interpretation of the data. As such, you need to be fully prepared when making a presentation with him in the room, and scheduled to speak right after you. #CSP2005

DrewMoghanaki's tweet photo. One of Dr. Altorki's greatest attributes is his honest interpretation of the data. As such, you need to be fully prepared when making a presentation with him in the room, and scheduled to speak right after you. #CSP2005 https://t.co/DKbwZqU5Ph

2

16

0

2K

Alejandro Bribriesco @abribriesco43

12 months ago

Update on status of #VALOR (#CSP2005) - #RCT of #Surgery vs #SBRT for early stage #LungCancer in surgical candidates in @DeptVetAffairs @tssmn @VAsurgeons @DrewMoghanaki @ClevelandVAMC @vadurham @hari_keshava @LorraineC_MD @PaulLinsky @girlceppa @ZaidAbdelsattar

Drew Moghanaki

@DrewMoghanaki

12 months ago

@ElliotServaisMD Insert David's finger in the bottom right figure.

0

13

3

2

4K

1

20

7

4

9K

Drew Moghanaki

@DrewMoghanaki

12 months ago

This picture captures the enduring joys of co-chairing the VALOR study with David Harpole, who is as kind and renowned a thoracic surgeon as the world has ever known. #WCLC25 #CSP2005 https://t.co/SIib8UK6iZ

DrewMoghanaki's tweet photo. This picture captures the enduring joys of co-chairing the VALOR study with David Harpole, who is as kind and renowned a thoracic surgeon as the world has ever known. #WCLC25 #CSP2005 https://t.co/SIib8UK6iZ https://t.co/A6yFG41L7G

2

23

3

2

2K

Drew Moghanaki

@DrewMoghanaki

12 months ago

That’s David Harpole at #WCLC25 pointing out that with 70% already accrued to the VALOR study, more than 120 participants have already completed their 5y follow-up period. #CSP2005

DrewMoghanaki's tweet photo. That’s David Harpole at #WCLC25 pointing out that with 70% already accrued to the VALOR study, more than 120 participants have already completed their 5y follow-up period. #CSP2005 https://t.co/mPXDjL9uNa

2

37

7

4

3K

Drew Moghanaki

@DrewMoghanaki

over 1 year ago

Long Beach VA just randomized 450!!! 🚀 🚀 🚀 @hari_keshava @medlawtalk #CSP2005

0

5

1

0

865

Drew Moghanaki

@DrewMoghanaki

over 1 year ago

Yes, that's Dr. Elizabeth Gore in the middle, our #radonc lead for the VALOR study, where she is also department chief. @NRGonc #CSP2005

Drew Moghanaki

@DrewMoghanaki

over 1 year ago

Few things make me prouder than the opportunity to serve our amazing Veterans. I trust @ZaidAbdelsattar and @abribriesco43 concur! https://t.co/Q56NVlrEov

DrewMoghanaki's tweet photo. Few things make me prouder than the opportunity to serve our amazing Veterans.

I trust @ZaidAbdelsattar and @abribriesco43 concur!

https://t.co/Q56NVlrEov https://t.co/GfZnPy8xsm

2

9

0

2K

0

3

1

0

2K

Drew Moghanaki

@DrewMoghanaki

almost 2 years ago

🚀 Still climbing 🚀 #CSP2005 https://t.co/YXyymBCZ5f

3

70

13

4

5K

Drew Moghanaki

@DrewMoghanaki

almost 2 years ago

I'm often asked whether the VALOR study is a non-inferiority study. From here forward, I will refer them to this article to help them understand why we didn't think that would be a wise use of resources. #CSP2005 https://t.co/BdG1BhlakD

DrewMoghanaki's tweet photo. I'm often asked whether the VALOR study is a non-inferiority study. From here forward, I will refer them to this article to help them understand why we didn't think that would be a wise use of resources. #CSP2005 https://t.co/BdG1BhlakD https://t.co/1KuGLFUwP8

1

25

5

12

3K

Drew Moghanaki

@DrewMoghanaki

almost 2 years ago

The VALOR Study team mascot enjoys a hike in the Santa Monica mountains.🌴 #CSP2005 #Valorie 🐕

2

18

0

1K

Drew Moghanaki

@DrewMoghanaki

almost 2 years ago

The Lung SBRT planning guideline for VALOR is now available for download. #CSP2005 https://t.co/uDzTjIuXDo

1

36

15

22

7K

Drew Moghanaki

@DrewMoghanaki

almost 2 years ago

@ShakeKumarMD @girlceppa @abribriesco43 @VAResearch @ClevelandVAMC @DurhamVAMC @VAsurgeons @kiranlagisetty @rvanharen @LorraineC_MD @DukeMBB Correction: Houston enrolled FOUR last month! The record is still held by Indianapolis who once randomized FIVE in a single month. #CSP2005

0

3

0

174

Drew Moghanaki

@DrewMoghanaki

almost 2 years ago

🚀🚀 400th patient randomized today 🚀🚀 #CSP2005 @VAResearch https://t.co/YXyymBCZ5f

1

46

7

1

4K

Drew Moghanaki

@DrewMoghanaki

almost 2 years ago

I've been thinking a lot about the patients older than 75 who participated in the CALGB 140503 study and were randomized to lobectomy (n=129). #WCLC24 #CSP2005

DrewMoghanaki's tweet photo. I've been thinking a lot about the patients older than 75 who participated in the CALGB 140503 study and were randomized to lobectomy (n=129). #WCLC24 #CSP2005 https://t.co/6HEOujV143

3

12

2

4

2K

Drew Moghanaki

@DrewMoghanaki

almost 2 years ago

The VALOR study team publishes its' observations evaluating the first 100 participants treated with lung SBRT through 2022. The planning guide is included in the appendix. Today, nearly 400 of 670 are randomized. #CSP2005 #radonc #ASTRO24 https://t.co/QWERtvnO1A

DrewMoghanaki's tweet photo. The VALOR study team publishes its' observations evaluating the first 100 participants treated with lung SBRT through 2022. The planning guide is included in the appendix. Today, nearly 400 of 670 are randomized. #CSP2005 #radonc #ASTRO24 https://t.co/QWERtvnO1A https://t.co/euQs20pEBq

4

100

29

24

8K

Top Tweets for #csp2005

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users